What Makes Sanofi (EPA:SAN) An Attractive Investment?
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Sanofi (ENXTPA:SAN) due to its excellent fundamentals in more than one area. SAN is a well-regarded dividend payer that has been able to sustain great financial health over the past. In the following section, I expand a bit more on these key aspects. For those interested in digger a bit deeper into my commentary, read the full report on Sanofi here.
Excellent balance sheet established dividend payer
SAN is financially robust, with ample cash on hand and short-term investments to meet upcoming liabilities. This implies that SAN manages its cash and cost levels well, which is a crucial insight into the health of the company. SAN appears to have made good use of debt, producing operating cash levels of 0.47x total debt in the prior year. This is a strong indication that debt is reasonably met with cash generated.
Income investors would also be happy to know that SAN is one of the highest dividend payers in the market, with current dividend yield standing at 4.41%. SAN has also been regularly increasing its dividend payments to shareholders over the past decade.
Next Steps:
For Sanofi, there are three relevant aspects you should further examine:
Future Outlook: What are well-informed industry analysts predicting for SAN’s future growth? Take a look at our free research report of analyst consensus for SAN’s outlook.
Historical Performance: What has SAN’s returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of SAN? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.